|
Age at surgery, years
|
|
Median (range)
|
58 (31–84)
|
|
Menopausal status
|
|
Pre-menopausal
|
63 (31.5)
|
|
Post- menopausal
|
137 (68.5)
|
|
Tumour size: cm in diameter
|
|
≤ 2
|
94 (47.0)
|
|
> 2
|
106 (53.0)
|
|
Nodal status
|
|
Node-negative
|
105 (52.5)
|
|
Node-positive
|
95 (47.5)
|
|
ER status
|
|
Poor (<10 % of stained cells)
|
42 (21.0)
|
|
Rich (≥10 % of stained cells)
|
158 (79.0)
|
|
PgR status
|
|
Poor (<10 % of stained cells)
|
86 (43.0)
|
|
Rich (≥10 % of stained cells)
|
114 (57.0)
|
|
Ki-67
|
|
Low (<14 % of stained cells)
|
91 (45.5)
|
|
High (≥14 % of stained cells)
|
109 (54.5)
|
|
HER2 status
|
|
Negative
|
183 (91.5)
|
|
Positive
|
17 (8.5)
|
|
Phenotypea
|
|
Luminal A
|
64 (32.0)
|
|
Luminal B (HER2-neg)
|
85 (42.5)
|
|
Luminal B (HER2-pos)
|
9 (4.5)
|
|
HER2 positive (non luminal)
|
8 (4.0)
|
|
Triple negative
|
34 (17.0)
|
|
Adjuvant systemic therapyb
|
|
No
|
87 (43.5)
|
|
Yes
|
113 (56.5)
|
